Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium

被引：0
|
作者：
Thitima Kongnakorn
Tereza Lanitis
Lievens Annemans
Vincent Thijs
Sophie Marbaix
机构：
[1] Evidera,Laboratory of Neurobiology
[2] Evidera,Experimental Neurology and Leuven Research Institute for Neurodegenerative Diseases (LIND)
[3] Ghent University (Ugent),Department of Neurology
[4] Vesalius Research Center,undefined
[5] VIB,undefined
[6] University of Leuven (KU Leuven),undefined
[7] University Hospital Leuven,undefined
[8] Pfizer,undefined
[9] Brussels University (VUB),undefined
来源：
Clinical Drug Investigation | 2014年 / 34卷
关键词：
Aspirin; Atrial Fibrillation; Major Bleed; Apixaban; Recurrent Stroke;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：709 / 721
页数：12
相关论文
共 50 条
  • [31] Non-valvular atrial fibrillation and stroke prevention
    Hankey, GJ
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (05) : 234 - 239
  • [32] BUDGET IMPACT ANALYSIS OF APIXABAN VERSUS OTHER NOACS FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Pradelli, L.
    Calandriello, M.
    Di Virgilio, R.
    Bellone, M.
    Tubaro, M.
    VALUE IN HEALTH, 2014, 17 (07) : A479 - A479
  • [33] COST-EFFECTIVENESS OF APIXABAN COMPARED TO ASPIRIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
    Lee, Soyon
    Anglade, Moise
    Hagstrom, Kelly
    Meng, Joy
    Kluger, Jeffrey
    Coleman, Craig
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E596 - E596
  • [34] STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION: SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES
    Costa, S.
    Ramos, J. C.
    Braga, A. C.
    Pereira, J.
    VALUE IN HEALTH, 2013, 16 (07) : A531 - A531
  • [35] Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation
    Sheldon M. Singh
    Harindra C. Wijeysundera
    Current Cardiology Reports, 2015, 17
  • [36] Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation
    Singh, Sheldon M.
    Wijeysundera, Harindra C.
    CURRENT CARDIOLOGY REPORTS, 2015, 17 (08)
  • [37] COST EFFECTIVENESS OF APIXABAN FOR STROKE PREVENTION IN NON VALVULAR ATRIAL FIBRILLATION IN THE ECUATORIAN PUBLIC HEALTHCARE SECTOR
    Rosado-Buzzo, A.
    Albuja, M.
    Garcia-Molliendo, L.
    Luna-Gasas, G.
    VALUE IN HEALTH, 2015, 18 (03) : A142 - A142
  • [38] Comparative cost-effectiveness of oral anticoagulants for stroke prevention in non-valvular atrial fibrillation patients in the UK
    Lip, G. Y. H.
    Lanitis, T.
    Kongnakorn, T.
    Phatak, H.
    Liu, L.
    Lawrence, J.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2015, 36 : 864 - 864
  • [39] COST-EFFECTIVENESS OF NOVEL ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN CHINA
    Guo, W.
    Tian, X.
    Li, W.
    Han, S.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [40] Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting
    Hori, Masatsugu
    Tanahashi, Norio
    Akiyama, Sayako
    Kiyabu, Grace
    Dorey, Julie
    Goto, Rei
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (03) : 252 - 261
12345